# Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer

> **NCT03880877** · PHASE2 · UNKNOWN · sponsor: **Kaohsiung Medical University Chung-Ho Memorial Hospital** · enrollment: 153 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Regorafenib
- **GENETIC:** UGT1A1 genotyping (TA6/TA6)
- **GENETIC:** UGT1A1 genotyping (TA6/TA7)
- **GENETIC:** UGT1A1 genotyping (TA7/TA7)
- **DRUG:** Leucovorin and 5-FU

## Key facts

- **NCT ID:** NCT03880877
- **Lead sponsor:** Kaohsiung Medical University Chung-Ho Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-26
- **Primary completion:** 2021-03-01
- **Final completion:** 2021-12-31
- **Target enrollment:** 153 (ESTIMATED)
- **Last updated:** 2019-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03880877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03880877, "Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03880877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*